Introduction
============

Acute promyelocytic leukemia (APL) is a distinct subtype of myeloid leukemia characterized by differentiation block resulting in accumulation of leukemic promyelocytes in the bone marrow. The disease is defined by a single genetic alteration involving chromosomal translocation 15;17, leading to the formation of oncogenic fusion protein PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha).^[@bib1],\ [@bib2],\ [@bib3]^ A minority of APL cases (\<5%) harbor fusion of *RARA* gene with other partners including *PLZF*, *NPM1*, *NUMA1* and *STAT5B.*^[@bib4],\ [@bib5]^ Although the translocations involving *RARA* are a constant event in APL, additional genetic events have been identified, including somatic alterations of *FLT3* and *NRAS* genes.^[@bib6],\ [@bib7]^ Moreover, expression of PML-RARA in mice is associated with long latency of onset of disease and variable penetrance.^[@bib8],\ [@bib9],\ [@bib10],\ [@bib11]^ This suggests that secondary genetic abnormalities contribute to the pathogenesis of APL. Sequencing of a mouse APL genome revealed recurrent mutations in *Jak1* and deletions comprising *Kdm6a* gene.^[@bib12]^ Previous next-generation sequencing studies, which have aimed to identify cooperating mutations in APL, were limited by either small sample size^[@bib13],\ [@bib14]^ or focus on newly diagnosed APL.^[@bib7]^

Targeted therapy with all-*trans* retinoic acid (ATRA) and arsenic trioxide (ATO) have revolutionized the treatment of APL in the past three decades.^[@bib15],\ [@bib16]^ Recent advances have included high efficacy of ATO as a frontline agent in newly diagnosed APL^[@bib17],\ [@bib18],\ [@bib19],\ [@bib20]^ and high rates of cure and shorter time to remission observed with the combination of ATRA and ATO.^[@bib21],\ [@bib22]^ Both ATRA and ATO target PML-RARA fusion protein and trigger its degradation by non-overlapping mechanisms, leading to restoration of normal retinoid signaling.^[@bib15],\ [@bib23]^ Despite the remarkable improvement in the treatment outcome in APL, a number of resistance-related treatment failures and relapses are observed in both ATRA- and ATO-treated APL.^[@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib24],\ [@bib25],\ [@bib26]^ Somatic mutations of *RARA* and *PML* genes associated with treatment resistance have been reported in APL relapse.^[@bib27],\ [@bib28],\ [@bib29],\ [@bib30],\ [@bib31],\ [@bib32]^ However, landscape of genetic aberrations acquired at relapse following these two discrete treatment regimens has not been systematically examined.

In this study, whole-exome and targeted exome sequencing of a large APL cohort was used to uncover mutational spectrum both at initial diagnosis and relapse. Samples from 212 APL cases (comprising 30 primary/relapse pair) including relapses arising subsequent to either ATRA or ATO treatment were analyzed. A mutational signature distinctive from other myeloid leukemias was identified and recurrent mutations of SWI/SNF members *ARID1A* and *ARID1B* were discovered. Sequencing data demonstrated that APL relapse is characterized by acquisition of frequent alterations in *PML* and *RARA* genes, specifically in ATO- and ATRA-treated cases, respectively. Our experiments also demonstrate that silencing of ARID1B leads to impaired differentiation of NB4 cells in response to ATRA.

Materials and methods
=====================

Sample collection and genomic DNA extraction
--------------------------------------------

Genomic DNA or frozen cell pellets from disease/remission stages were obtained from various institutes and hospitals. Informed consent was obtained in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of respective institutes. Genomic DNA was extracted from cell pellets using DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA). DNA was quantified using Qubit Fluorometer (Life Technologies, Carlsbad, CA, USA) and DNA integrity was assessed by agarose gel electrophoresis. DNA was amplified using REPLI-g UltraFast Mini Kit (Qiagen) for samples with insufficient quantity. DNA was sheared using Covaris instrument (Woburn, MA, USA) and assessed on 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) before library preparation.

Whole-exome and targeted capture sequencing
-------------------------------------------

For whole-exome sequencing, DNA libraries were prepared using SureSelect Human All Exon (50 Mb) Kit (Agilent), as per the manufacturer\'s instructions. For targeted capture library, customized RNA baits were designed to capture exons of 398 genes. Libraries were prepared using SureSelect XT2 Target Enrichment System (Agilent) for Illumina Multiplexed Sequencing and sequenced on HiSeq 2000 platform (Illumina, San Diego, CA, USA).

Somatic variant discovery and validation
----------------------------------------

Paired-end reads of 100 bp were aligned to hg19 reference genome using bwa mem (<http://arxiv.org/abs/1303.3997v2>) in default mode. Duplicates were marked with Samblaster.^[@bib33]^ Resulting bam files were further processed according to Genome Analysis Toolkit (GATK) best practices (<https://www.broadinstitute.org/gatk/guide/bp_step.php?p=1>), by performing Indel Realignment and Base Quality Recalibration. Minimum mapping quality of 15 was considered for variant calling. Somatic variants were called using two methods: ebCall^[@bib34]^ and VarScan2 (version 2.3.8).^[@bib35]^ Mutations supported by either \<5 reads or those supported by reads in only one direction were excluded. Also, variants with variant allele frequencies \<0.05 were disregarded. Processed somatic variants were later filtered for false positives using varscan2 fpfilter command. Final confident variants were annotated using annovar and oncotator. Commonly found SNPs in general population were filtered out using dbSNP135, 1000 Genomes and our in-house SNP databases, while retaining the clinically associated variants. For samples without germline samples, we retained variants that passed the criteria outlined in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}. Oncoplots were drawn using mafTools (<https://github.com/PoisonAlien/mafTools>) and ComplexHeatmap bioconductor package. Clonality analysis was carried out using sciClone.^[@bib36]^ Mutual exclusion relationships between frequently mutated genes were assessed by Mutation-Relation Test.^[@bib37]^ All somatic mutations reported in this study were validated by Sanger sequencing. The sequencing data have been deposited in the NCBI Sequence Read Archive under accession code SRP070515.

Generation of ARID1B knockdown cell lines
-----------------------------------------

Short hairpin (sh) RNA sequences were cloned into *Age*I/*Eco*RI sites of pLKO.1 lentiviral vector (Sigma, St Louis, MO, USA) and viral particles were generated by transfection in 293T cells, as described previously.^[@bib38]^ Viral supernatant was collected 48 and 72 h after transfection, and used to transduce NB4 cells (provided by Dr Wee Joo Chng, Singapore) two times, 24 h apart. Cells were selected in puromycin to generate stably knockdown cell lines. The target sequence for human ARID1B sh2 and sh3 are 5′-GCAGGACATGTACAACCAAAG-3′ and 5′-GCCGAATTACAAACGCCATAT-3′, respectively.

Results
=======

Analysis of APL exomes at diagnosis and relapse
-----------------------------------------------

Whole-exome sequencing was used to characterize the genetic alterations in 12 primary diagnosis APL with eight matched relapse samples ([Table 1](#tbl1){ref-type="table"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Complete remission samples that were negative for *PML-RARA* fusion allele were used as germline control. We achieved a mean depth of 117x (range 79--159x) and an average 81% of nucleotides were covered by at least 20 reads ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). We validated a total of 115 somatic non-silent mutations in 109 genes using Sanger sequencing ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). We observed that the average number of nonsynonymous and synonymous mutations at relapse remained unchanged compared with the initial diagnosis (two-tailed Student\'s *t*-test) ([Figure 1a](#fig1){ref-type="fig"}). Recurrent mutations were observed in *FLT3*, *WT1* and *PML* genes, with mutations of *PML* detected only in relapse samples. Mutations in other novel genes such as *ARID1A*, *CEBPE*, *AKT1*, *KAT6A* and *HK3* were also detected in one sample each ([Supplementary Table S2](#sup1){ref-type="supplementary-material"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Among the eight diagnosis--relapse pairs, six samples had mutations that were shared between the two disease stages, indicating re-emergence of disease subclone following therapy ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Although, no non-silent mutation common to both diagnosis and relapse was detected in DS1 and DS6, PML-RARA fusion was the common genetic lesion, indicating that the relapse evolved from an ancestral clone ([Figure 1b](#fig1){ref-type="fig"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Although sequencing depth was inadequate to discover minor subclones, clustering analysis outlined an evolutionary pattern where the founding clone or a subclone at primary disease acquired additional lesions at relapse (number of variants in DS11 were insufficient for clustering) ([Figure 1b](#fig1){ref-type="fig"}), similar to as previously described for acute myeloid leukemia (AML).^[@bib39],\ [@bib40],\ [@bib41]^

Mutational topography of primary APL
------------------------------------

Next, to uncover the repertoire of somatic mutations in APL, targeted sequencing was performed on exons of 398 genes, including 109 genes identified in our discovery cohort. The additional genes (listed in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}) comprised those either previously implicated in hematological malignancies or identified in earlier leukemia sequencing studies. In this frequency cohort, we sequenced 22 paired diagnosis and relapse samples. In addition, 131 unpaired newly diagnosed and 47 unpaired relapse samples, making a total of 200 individual APL samples, were also sequenced ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). The number of samples analyzed in this study is summarized in [Table 1](#tbl1){ref-type="table"}. The mean sequencing depth was 272x (range 40--865x), with 90% of target bases covered \>20x ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). C--T transition was the most frequent nucleotide substitution at both primary and relapse APL ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}).

To identify significantly mutated genes in APL, we excluded from further analysis several genes (listed in [Supplementary Table S5](#sup1){ref-type="supplementary-material"}) that frequently exhibit high rate of variants because of large size and constitute potential false positives in cancer sequencing studies.^[@bib42],\ [@bib43]^ Somatic variants identified in bioinformatics analysis were verified using Sanger sequencing. Overall, 210 non-silent point mutations and small insertions/deletions were validated in our frequency cohort. In addition, the presence of FLT3-ITD (fms-like tyrosine kinase 3-internal tandem duplication) was examined using the Genomon ITDetector^[@bib44]^ and verified using PCR analysis.

Our collective analysis of discovery and frequency cohorts revealed *FLT3* as most frequently altered gene in primary APL ([Figure 2](#fig2){ref-type="fig"}), similar to observation in an earlier study.^[@bib7]^ This included 27% cases with FLT3-ITD (45 out of 165 initial diagnosis samples) and 16% cases (26 mutations in 25 samples) with point mutations of *FLT3* ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Tables S1](#sup1){ref-type="supplementary-material"}). In fact, alteration of *FLT3* gene was a sole genetic aberration present in 25% of newly diagnosed APL cases (39/153 in frequency cohort), signifying their cooperativity with PML-RARA fusion in driving the disease. The somatic mutations of *FLT3* predominantly occurred in the tyrosine kinase domains 1 and 2 and in the juxtamembrane domain, with D835 residue most frequently mutated (18/27 cases) ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"} and [Supplementary Tables S2 and S6](#sup1){ref-type="supplementary-material"}). Other known AML genes that were recurrently mutated in our cohort included *WT1* (14%), *NRAS* (10%), *KRAS* (4%), *ETV6* (1%) and *EZH2* (1%) ([Figure 2](#fig2){ref-type="fig"}). Mutations of *NRAS* gene clustered at amino-acid residues G12, G13 and V14, whereas *KRAS* mutations occurred at G12 and Q61 residues ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"} and [Supplementary Table S6](#sup1){ref-type="supplementary-material"}). In addition, missense mutations at K117 and A146 were also detected in *KRAS*. Majority of *WT1* mutations resulted in truncated protein (seven nonsense, seven frameshift insertions/deletions and one splice site mutation out of 23 mutations). In addition, eight missense substitutions were clustered in the C-terminus region encoding Zn-finger domains ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). Our sequencing analysis also revealed the absence of FLT3-ITD or non-silent mutation in any known driver genes in a quarter of primary APL samples (27% 43/153 frequency cohort), suggesting that a single detectable genetic lesion (PML-RARA fusion) was sufficient to drive the disease.

Mutation-relation test^[@bib37]^ was used to examine the association between mutations identified in primary APL. FLT3-ITD rarely co-occurred with mutations in *FLT3* or *WT1* genes (*P*\<0.01). Similarly, mutations of Ras pathway genes (*NRAS* and *KRAS*) were predominantly detected in cases with wild-type *FLT3* (FLT3-ITD vs *NRAS* mutation, *P*=0.022; FLT3-ITD vs *KRAS* mutation, *P*=0.024; *FLT3* mutation vs *NRAS* mutation, *P*=0.027).

APL exhibits distinct mutational signature among myeloid leukemia
-----------------------------------------------------------------

Sequencing of a large cohort enabled us to contrast the mutational pattern of APL to other AML subtypes. Mutational frequencies of recurrently mutated genes in newly diagnosed APL were compared with non-M3 AML samples in TCGA data set. Somatic mutations in known leukemia-related genes (e.g. *DNMT3A*, *NPM1*, *TET2*, *IDH1*, *IDH2* and *ASXL1*) were absent or rarely observed in APL ([Figure 3a](#fig3){ref-type="fig"}). This was evident not only in the primary disease, as previously noted by Welch *et al.*,^[@bib7]^ but also at relapse (two cases with mutation of *TET2*; one case with mutations of *DNMT3A*; no mutation of *NPM1*, *ASXL1*, *IDH1* and *IDH2* genes were observed in our study) ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). An increased incidence of *FLT3* alterations occurred in APL compared with other AML subtypes, although the difference did not reach statistical significance (FLT3-ITD: 27.3% in APL vs 18.9% in other AML, *P*=0.191; mutant *FLT3*: 15.8% in APL vs 9.7% in other AML, *P*=0.078) ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). On the other hand, mutational frequency of other known drivers such as *NRAS*, *KRAS*, *EZH2* and *ETV6* were comparable between primary APL and other AML ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). Our sequencing data also revealed recurrent mutations in several genes either previously unidentified in APL or mutated at higher frequency compared with other AML subtypes. These included two members of the SWI/SNF complex, *ARID1B* and *ARID1A* (Fisher\'s exact test, *P*\<0.05), both of which exhibited high proportion of loss-of-function alterations including frameshift insertions/deletions or nonsense mutations ([Figures 3a--c](#fig3){ref-type="fig"}). We also noted recurrent mutations of other lesser recognized genes such as *CEBPE*, *NUMA1*, *RUNX1T1*, *HUWE1*, *HK3* and *USP9X*. These observations highlight a distinctive mutational profile for APL, distinguishing it from other AML subtypes.

Landscape of somatic mutations at APL relapse
---------------------------------------------

To obtain insights into mutations either specifically present or enriched in APL relapse, mutational frequencies at initial diagnosis and relapse (morphological relapses) were compared. Significantly, higher frequency of mutations in four genes were detected in relapse samples, including *PML*, *RARA*, *RUNX1* and *ARID1B* (Fisher\'s exact test; *P*\<0.05) ([Figure 4a](#fig4){ref-type="fig"}). FLT3-ITD was the most frequent lesion at relapse, at a frequency similar to that observed at primary APL. On the other hand, mutations of *FLT3* were enriched in the primary APL samples and their incidence in relapse samples was significantly reduced (15.8% in diagnosis vs 5.2% in relapse; Fisher\'s exact test; *P*\<0.05) ([Figures 2](#fig2){ref-type="fig"} and [4a](#fig4){ref-type="fig"}). Similar to the pattern observed in *FLT3*, mutations of both *NRAS* and *KRAS* occurred at a higher frequency in newly diagnosed samples compared with the relapse, albeit the difference in their mutational frequencies between the two stages did not reach statistical significance (*NRAS*: 9.7% in newly diagnosed and 5.2% in relapse; *KRAS*: 3.6% in primary APL and 1.3% in relapse). On the other hand, mutational frequency of *WT1* did not vary significantly between diagnosis and relapse stages (13.9% in primary APL and 18.2% in relapse).

Missense mutations of *RARA* were detected in seven relapse cases (eight mutations), all of which harbored mutations in the ligand-binding domain. One sample (222 R) had a second mutation of *RARA* (R217P) present in the vicinity of ligand-binding domain ([Figure 4b](#fig4){ref-type="fig"}). Three samples (four mutations), where RNA was available, showed that all four mutations of *RARA* were present in the *PML-RARA* fusion allele ([Supplementary Figure S8](#sup1){ref-type="supplementary-material"}). Similar mutations affecting the ligand-binding domain of *RARA* in the *PML-RARA* allele have also been reported previously.^[@bib28],\ [@bib45]^ Thirteen mutations of *PML* (in 11 cases) were observed in relapse APL, of which 12 were clustered in the B2 domain, and A216V was the most frequent alteration ([Figure 4c](#fig4){ref-type="fig"}). Although mutations in close proximity of C212-C213 dicysteine residues, which are involved in binding to PML, have been described, a missense mutation at N191 in B2 domain was also identified. A frameshift deletion in a shorter PML isoform (NM_033249; S482) was also detected in relapse APL. In addition, a newly diagnosed case harbored a missense mutation at E699 (its matched relapse sample was not available). One relapse case (249 R) harbored two mutations (a missense and a nonsense point mutation) at the C213 residue, indicating that both *PML* alleles were affected. RNA was available for three cases, of which two cases harbored mutations in the *PML-RARA* allele ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}). However, one case had mutations of D219-S220 dinucleotide in the wild-type *PML* allele ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}), indicating that disruption of normal PML function may have implications in APL.

We categorized our relapse samples into two groups, based on the treatment approach used at the primary disease, which was either ATRA (with or without chemotherapy) or arsenic trioxide ([Table 1](#tbl1){ref-type="table"}). Using this classification, a divergence was observed in the mutational pattern of *PML* and *RARA* genes in relapse following ATO and ATRA therapy, respectively. While 12 of 13 *PML* mutations (10/11 cases) occurred in post-ATO relapse, *RARA* mutations were more frequent post-ATRA treatment (6/8 mutations of *RARA* were detected post-ATRA treatment) (in 5 of 7 cases). Interestingly, one relapse sample (245 R; post-ATO relapse) had mutations of both *PML* and *RARA* genes ([Supplementary Tables S4 and S6](#sup1){ref-type="supplementary-material"}).

Although *RUNX1* mutations were rare in newly diagnosed APL, they occurred at a higher frequency at relapse (0.6% at primary APL and 6.5% at relapse) ([Figure 4d](#fig4){ref-type="fig"}). Interestingly, five of the six mutations of *RUNX1* were either frameshift insertion/deletions or nonsense mutations ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). Notably, we observed that mutations in *ARID1B* were also significantly enriched at relapse (3.0% at initial diagnosis and 11.7% at relapse), whereas *ARID1A* was mutated at a similar frequency at both stages of disease (4.8% at initial diagnosis and 5.2% at relapse). Both genes predominantly exhibited loss-of-function mutations, and two cases (159D and 210 R) harbored frameshift insertions of both *ARID1A* and *ARID1B* ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). Moreover, three cases with *ARID1B* mutations also harbored *PML* mutations, indicating cooperativity between the two genes ([Figure 4a](#fig4){ref-type="fig"}).

Knockdown of ARID1B leads to impaired differentiation of NB4 cells
------------------------------------------------------------------

Next, we investigated the functional consequences of the loss of ARID1B, one of the novel mutated gene in APL, on growth and differentiation of APL cells. To replicate the deficiency of ARID1B caused by truncating lesions, we used shRNA-mediated gene knockdown approach to stably downregulate expression of ARID1B in NB4 cells. Two shRNA sequences (sh2 and sh3) significantly silenced the expression of ARID1B at both the transcript and protein levels ([Figures 5a and b](#fig5){ref-type="fig"}), without affecting the expression of ARID1A, a closely related member of ARID1 family ([Supplementary Figure S10](#sup1){ref-type="supplementary-material"}). Suppression of ARID1B did not significantly alter the growth of NB4 cells in liquid culture over 4 days ([Supplementary Figure S11](#sup1){ref-type="supplementary-material"}). In the colony-forming assay, ARID1B knockdown cells exhibited a moderate increase in the number of colonies observed after 9 days ([Figure 5c](#fig5){ref-type="fig"}). NB4 cells can undergo granulocytic differentiation upon ATRA treatment, and we used this *in vitro* model to assess the differentiation of ARID1B-deficient cells. We noticed that knockdown of ARID1B resulted in a small increase in CD11b expression compared with control shRNA-transduced cells without stimulation with ATRA ([Supplementary Figure S12](#sup1){ref-type="supplementary-material"}). Treatment of cells with different concentrations of ATRA-induced expression of CD11b in a dose- and time-dependent manner. However, increase in the proportion of CD11b-expressing cells in ATRA- vs vehicle-treated cells was lower in the ARID1B knockdown cells compared with the control cells. This observation suggests a role of ARID1B in *in vitro* differentiation towards the granulocytic lineage.

Gene expression changes induced by silencing of ARID1B
------------------------------------------------------

We performed RNA sequencing of control and ARID1B knockdown NB4 cells to examine transcriptomic changes caused by suppression of ARID1B. Gene expression analysis revealed differential expression of 1028 genes (false discovery rate \<0.05). Significantly, expression of a majority of genes (740/1028) was elevated in the ARID1B knockdown cells compared with the control cells, whereas 288 genes were downregulated ([Figure 6a](#fig6){ref-type="fig"} and [Supplementary Figure S13](#sup1){ref-type="supplementary-material"}). Gene ontology analysis of upregulated genes showed a marked enrichment for several pathways related to immune response, signal transduction and hematopoietic differentiation, whereas downregulated genes were over-represented for cell adhesion and WNT signaling ([Figure 6b](#fig6){ref-type="fig"}). Using quantitative real time-PCR, we validated elevated expression of several genes involved in hematopoietic development and immune regulation in ARID1B knockdown cells. These included *GATA1*, *GATA2*, *IKZF2*, *NFE2*, *IRF5*, *BPI*, *PRG2* and *PRTN3*, whereas the expression of *WNT7B* and *HOXC4* was downregulated ([Figure 6c](#fig6){ref-type="fig"}). In accordance with increased expression of GATA1 and GATA2, gene set enrichment analysis verified upregulation of their target genes in ARID1B knockdown NB4 cells ([Supplementary Figure S14](#sup1){ref-type="supplementary-material"}).

Discussion
==========

This study provides the most comprehensive profiling of somatic mutations in APL to date, at both initial diagnosis and relapse. We demonstrate that the mutational spectrum of APL is notably different from other AML subtypes. Overall, the topography of somatic mutations in APL is defined by recurrent alterations of *FLT3*, *WT1*, *NRAS*, *KRAS*, *ARID1B* and *ARID1A* genes, and the absence of mutations in other common AML genes incluing *DNMT3A*, *NPM1*, *TET2*, *ASXL1* and *IDH1/2*. Moreover, the repertoire of mutations at relapsed APL differs significantly from newly diagnosed cases and is characterized by alterations in *PML* and *RARA* genes, which are rarely affected by somatic mutations in primary APL. In our cohort, matched diagnosis samples were available for three relapse cases (DS4R, DS6R, 243 R) harboring four *PML* mutations and one case (29 R) harboring *RARA* mutation, all of which were negative for the corresponding mutations of *PML* and *RARA* genes. We also uncovered increased frequency of *ARID1B* and *RUNX1* mutations in APL relapse. In addition, the mutational frequency of *FLT3* was considerably lower at relapse compared with primary disease, although the proportion of FLT3-ITD was similar at the two stages of disease.

APL is distinctive from other AML subclasses in its sensitivity to ATRA- and ATO-based therapies. In this study, we also examined relapse-specific mutations in the context of therapeutic intervention used at the initial diagnosis. Notably, our relapse cohort comprised of sizable number of ATRA-free ATO-treated samples. We found that the incidence of mutations in *RARA* and *PML* genes largely segregated into post-ATRA and post-ATO relapses, respectively. This indicates distinct mechanisms are involved in acquisition of resistance following two different therapeutic regimens.

Our RT-PCR experiments for allele-specific analyses show that mutations of *RARA* invariably occurred on the *PML-RARA* fusion allele, similar to previous studies.^[@bib28],\ [@bib45]^ Mutations of *PML* occurred in proximity to the C212-C213 dicysteine residues, which is associated with binding of ATO to PML moiety.^[@bib46],\ [@bib47]^ These mutations of *PML* in the B2 domain are associated with resistance to arsenic therapy.^[@bib30],\ [@bib32]^ Although an initial report showed that mutations of *PML* in two ATO-resistant cases occurred on the *PML-RARA* allele and accounted for an impaired response to therapy,^[@bib30]^ we detected mutations of *PML* either on the rearranged (two cases) or the wild-type *PML* allele (one case). A recent report noted a mutation in the non-rearranged allele of *PML* gene in a case which presented with multiple relapses.^[@bib31]^ Also, truncating mutations of wild-type *PML* allele have been observed in ATRA-resistant APL,^[@bib29]^ indicating that mutations affecting either allele of *PML* may have pathological consequences.

Our sequencing data uncover recurrent mutations in two novel genes, *ARID1B* and *ARID1A*, in APL. Somatic mutations in these two members of SWI/SNF chromatin remodeling complex are very frequent in gynecologic and several other solid tumors.^[@bib48],\ [@bib49],\ [@bib50]^ However, incidence of somatic alterations in genes of ARID1 family is rare in myeloid leukemia,^[@bib7],\ [@bib51]^ although, recently, mutations of *ARID1A* have been detected in other hematological malignancies including chronic lymphocytic leukemia, natural killer/T-cell lymphoma and hairy cell leukemia.^[@bib52],\ [@bib53],\ [@bib54]^ Notably, large majority of mutations in both *ARID1B* and *ARID1A* in APL were loss-of-function alterations, similar to the truncating mutations observed in solid tumors.

Germline mutations and chromosomal aberrations affecting *ARID1B* are associated with disorders characterized by developmental delay and intellectual disability including Coffin-Siris syndrome.^[@bib55],\ [@bib56]^ Although mutations of *ARID1B* have been reported in solid tumors, to our knowledge, this is the first report of *ARID1B* alterations in myeloid leukemia. Interestingly, mutations of *ARID1B* were more frequent at relapse APL compared with the newly diagnosed cases in our cohort. Our experiments show that the knockdown of ARID1B does not significantly modulate either the cell growth or colony-forming ability *in vitro*; however, it alters the differentiation of NB4 cells in response to ATRA. Transcriptome analysis showed that silencing of ARID1B resulted more prominently in activation of gene expression, suggesting it potentially functions as a repressor of gene expression.

Several other potentially novel drivers of leukemia were also identified at low mutational frequencies in this study. Among them, mutations in the transcription factor *CEBPE* were observed in three cases (two primary and one relapse APL), all of which were potentially deleterious alterations (frameshift insertion/deletion and splice site mutation). Loss-of-function germline alteration of *CEBPE* causes specific granule deficiency, a rare congenital disorder characterized by neutrophils with abnormal nuclear morphology, impaired function and lacking secondary and tertiary granule proteins.^[@bib57]^ However, somatic mutations of *CEBPE* in myeloid leukemia have not been previously identified. CEBPE is a critical regulator of granulocytic differentiation and truncating mutations in this gene may have implications on differentiation of promyelocytes. Another interesting candidate is a hexokinase gene, *HK3*, which was mutated in three APL cases. HK3 is specifically expressed during granulocytic differentiation and was previously shown to be downregulated in APL.^[@bib58]^ Silencing of HK3 also resulted in impaired ATRA-induced granulocytic differentiation of NB4 cells.^[@bib58]^ Four somatic mutations (in three cases) in *NUMA1* gene, located on chromosome 11 and involved in t(11;17)(q13;q21) translocation to form NUMA1-RARA fusion in variant cases of APL,^[@bib59]^ were also observed. Two primary APL cases harbored mutations of *RUNX1T1*, a gene fused with *RUNX1* in AML characterized by t(8;21) translocation. *USP9X*, an X-linked intellectual disability gene,^[@bib60]^ which encodes for a deubiquitinase enzyme, was mutated in four APL cases. Although the function of USP9X in hematopoietic development has not been defined, all four mutations of *USP9X* were potentially damaging alterations (three frameshift deletion and one splice site substitution). The pathogenic implications of these novel mutations in the development of APL remain to be investigated.
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![Characteristics of somatic mutations detected at primary and relapse APL. (**a**) Comparison of mutational load between primary and relapse APL. Boxplots depict median and range for numbers of nonsynonymous and synonymous variants identified per exome. Difference between average number of variants between two groups was estimated using two-tailed Student\'s *t*-test. (**b**) Clustering analysis using variant allele frequencies (VAFs) of all somatic variants (VAF ⩾0.08) observed at primary and relapse APL. DS2 and DS6 are shown as two representative cases, which harbor common or exclusive somatic mutations, respectively, at initial diagnosis and relapse.](leu201669f1){#fig1}

![Recurrently mutated genes in primary APL. Mutational topography of newly diagnosed APL is depicted. Top 20 mutated genes validated by Sanger sequencing are shown and are color-coded for various types of mutation. Genes are displayed according to decreasing mutational frequency from top to bottom. Samples are displayed as columns and arranged to emphasize mutual exclusivity. Samples in which either no driver mutation was detected in our analysis pipeline or do not harbor mutations of top 20 genes are not included in the matrix. Bars on the right side depict absolute number of mutations in each gene.](leu201669f2){#fig2}

![Distinct mutational profile of newly diagnosed APL. (**a**) Bars represent mutational rates of genes mutated at significantly different frequencies (Fisher\'s exact test; *P*\<0.05) between APL and other AML subtypes at initial diagnosis. Frequency of validated non-silent mutations in 165 newly diagnosed APL samples analyzed in this study was compared with 176 non-APL AML samples from the TCGA database. *TTN*, which is most frequently mutated in public exomes,^[@bib42]^ and *MT-CYB*, which was not included in our targeted sequencing, were excluded from this representation. (**b** and **c**) Schematic representation of protein domains of ARID1A (**b**) and ARID1B (**c**) was drawn with DOG 2.0 software (<http://dog.biocuckoo.org>) using domain information from NCBI Protein database (<http://www.ncbi.nlm.nih.gov/protein>). Location and type of all somatic mutations verified at primary and relapse APL are shown. Circles depicting individual mutations are color-coded for different types of mutations.](leu201669f3){#fig3}

![Spectrum of somatic mutations at APL relapse. (**a**) Matrix displays top 15 genes recurrently mutated at relapsed APL. Each column represents a relapse sample. Genes are arranged according to decreasing mutational frequencies from top to bottom. Right panel illustrates the number of mutations for all genes. Only those relapse samples that harbor mutations of top 15 genes are included in the matrix. (**b**--**d**) Protein domains for RARA (**b**), PML (**c**) and RUNX1 (**d**) are drawn using the DOG 2.0 software (<http://dog.biocuckoo.org>), and type and location of validated mutations are illustrated. Information about protein domains was obtained from Human Protein Reference Database (<http://www.hprd.org>). All except one missense mutation (E699K) of PML were found in relapse samples. One frameshift deletion in *PML* transcript NM_033249 (NP_15025; S482fs) is not shown. All mutations of *RARA* were detected in relapse. Only one of the six mutations of RARA occurred in newly diagnosed samples.](leu201669f4){#fig4}

![Silencing of ARID1B impairs ATRA-induced neutrophil differentiation of NB4 cells. (**a** and **b**) Generation of NB4 cells with stable knockdown of ARID1B. Cells transduced with ARID1B shRNA (sh2 or sh3) display significant suppression of ARID1B transcript (two primer pairs) (**a**) and protein levels (**b**) compared with the control transduced (con) cells. Glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) transcript levels were used to normalize for RNA in quantitative real time-PCR (qRT-PCR) analysis in (**a**) and bars represent mean±s.d. (**c**) Clonogenic ability of ARID1B knockdown NB4 cells compared with control cells. Cells were plated in methylcellulose media, and colonies were enumerated after 9 days. Bars represent mean±s.e.m. (**d**) ATRA-induced differentiation of control and ARID1B knockdown NB4 cells was determined by surface expression of CD11b. Cells were treated with 0.1, 1 or 10 μ[m]{.smallcaps} ATRA, and the proportion of CD11b-expressing cells was determined by flow cytometry at indicated times. The difference in the percentage of CD11b^+^ cells obtained in ATRA- vs DMSO-treated cells at each time point is depicted. Data represent mean±s.e.m. of four to five experiments (\**P*\<0.05; Student\'s *t*-test).](leu201669f5){#fig5}

![Gene expression changes in ARID1B knockdown NB4 cells. (**a**) Volcano plot depicts differentially expressed genes between ARID1B knockdown (sh2 and sh3) and control transduced NB4 cells. Horizontal line denotes false discovery rate (FDR)=0.05. Blue dots represent genes involved in 'immune system process\' GO:0002376. (**b**) Functional enrichment analysis (gene ontology) of genes either upregulated or downregulated in ARID1B knockdown NB4 cells (FDR\<0.05). (**c**) qRT-PCR analyses of selected genes identified as differentially expressed in RNA sequencing. *GAPDH* was used as an endogenous control to normalize for RNA quantity. Bars represent mean±s.e.m.](leu201669f6){#fig6}

###### Dx and Rel APL samples sequenced in this study

  ------------------------------------ ----------------- --------------- ----------------
  *Number of samples*                                                    
   Dx                                      165 (147)                      
   Rel                                      77 (40)                       
   Total                                   242 (187)                      
                                                                          
                                        *Paired Dx+Rel*  *Unpaired Dx*   *Unpaired Rel*
  *Sample specifics*                                                     
   Discovery cohort (whole exome)            8 (8)       4 (4)           0
   Frequency cohort (targeted exome)        22 (14)      131 (121)       47 (18)
   Total                                    30 (22)      135 (125)       47 (18)
                                                                          
  *Relapse (prior therapy at Dx)*                                        
   ATRA                                       33                          
   ATO                                        41                          
   Information unavailable                     3                          
                                                                          
  *Age (at diagnosis)*                                                   
   Median                                  37 years                       
   Range                                  4-69 years                      
                                                                          
  *Gender*                                                               
   Male                                      56.7%                        
   Female                                    43.3%                        
  ------------------------------------ ----------------- --------------- ----------------

Abbreviations: APL, acute promyelocytic leukemia; Dx, newly diagnosed; Rel, relapse.

Numbers within parentheses represent the number of samples with matched germline control.
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